维普中文期刊产品整合服务
79篇 您的检索式:作者名="HOLGER R"
    题名 作者 年代 出处 被引量
1The potential molecular mechanism of overexpression of uPA, IL-8, MMP-7 and MMP-9 induced by TRAIL in pancreatic cancer cell显示文摘BACKGROUND:TNF-related apoptosis-inducing ligand (TRAIL) is a death ligand of the TNF-superfamily that has been implicated in inducing apoptosis in some tumor cells. The purpose of this study was to find out if TRAIL could induce the expression of uPA, IL-8, MMP-7 and MMP-9. and to explore the corresponding potential signaling transduction pathway in pancreatic cancer cells. METHODS:Colo357wt, Panc89 and PancTuⅠ cell lines were stimulated by TRAIL (100 ng/ml). Crystal violet cell vitality assay was used to check the sensitivity to TRAIL-induced apoptosis. Real-time RT-PCR tested the expression of uPA, IL-8, MMP-7 and MMP-9. RESULTS:TRAIL can stimulate the expression of uPA, IL-8, MMP-7 and MMP-9 in pancreatic cancer cell lines, especially in Colo357wt. The members of caspases, MEK1/2, PKC, and NF-κB are involved in TRAIL-induced expression of uPA, IL-8, MMP-7 and MMP-9. Furthermore, caspases play a different role in Colo357wt, Panc89 and PancTuⅠ. CONCLUSIONS:TRAIL-treatment may result in the enhancement of invasion involving the signaling pathways of caspases, MEK1/2, PKC and NF-κB, in pancreatic cancer cells. It points to the necessity to carefully evaluate in vivo side effects of TRAIL.Anna Trauzold Christian Rder Holger Kalthoff 2008Hepatobiliary & Pancreatic Diseases International2008,7,2:6
2TRAIL-induced expression of uPA and IL-8 strongly enhanced by overexpression of TRAF2 and Bcl-xL in pancreatic ductal adenocarcinoma cells显示文摘BACKGROUND:The death ligand,tumor necrosis factor(TNF)related apoptosis-inducing ligand(TRAIL),induces apoptosis and non-apoptotic signaling in some tumor cells.The purpose of this study was to investigate the roles of the pro-apoptotic TRAIL receptors,TRAIL-R1 and TRAIL-R2,as well as Bcl-xL and TRAF2 in TRAIL-induced expression of the pro-inflammatory cytokine IL-8 and the invasion-promoting protein urokinase(uPA) in pancreatic ductal adenocarcinoma(PDAC) cells.METHODS:Colo357wt,Colo357/TRAF2,Colo357/Bcl-xL,Panc89 and PancTuI cells were stimulated with TRAIL and uPA and IL-8 expression was detected using real-time PCR.Antagonistic,receptor-specific antibodies were used to investigate the effects of TRAIL-R1 or TRAIL-R2 inhibition.RESULTS:Dose-dependent increases in uPA and IL-8 expression were detected following TRAIL stimulation in PDAC cells.These effects were inhibited when TRAIL-R1 but not TRAIL-R2 was blocked.Overexpression of TRAF2 or Bcl-xL strongly increased TRAIL-mediated upregulation of uPA and IL-8.CONCLUSIONS:In PDAC cells,TRAIL strongly induced uPA and IL-8 via TRAIL-R1.This response was further enhanced in cells overexpressing TRAF2 and Bcl-xL.Therefore,inhibition of the non-apoptotic 'side-effects' of TRAIL treatments by inactivation of TRAF2 and Bcl-xL might represent additional relevant strategies for the treatment of pancreatic cancer.Dong-Hui Zhou Li-Na Yang Christian Rder Holger Kalthoff Anna Trauzold 2013Hepatobiliary & Pancreatic Diseases International2013,12,1:5
3A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform显示文摘Bence Sipos Simone M?ser Holger Kalthoff Virag T?r?k Matthias L?hr Günter Kl?ppel 2003Virchows Archiv2003,,5:4
4Paclitaxel-eluting balloon dilation of biliary anastomotic stricture after liver transplantation显示文摘AIM:To investigate the safety and effectiveness of endoscopic therapy with a paclitaxel-eluting balloon(PEB) for biliary anastomotic stricture(AS) after liver transplantation(LT).METHODS:This prospective pilot study enrolled 13 consecutive eligible patients treated for symptomatic AS after LT at the University Hospital of Münster between January 2011 and March 2014.The patients were treated by endoscopic therapy with a PEB and followed up every 8 wk by endoscopic retrograde cholangiopancreatography(ERCP).In cases of re-stenosis,further balloon dilation with a PEB was performed.Follow-up was continued until 24 mo after the last intervention.RESULTS:Initial technical feasibility,defined as successful balloon dilation with a PEB during the initial ERCP procedure,was achieved in 100% of cases.Long-term clinical success(LTCS),defined as no need for further endoscopic intervention for at least 24 mo,was achieved in 12 of the 13 patients(92.3%).The mean number of endoscopic interventions required to achieve LTCS was only 1.7 ± 1.1.Treatment failure,defined as the need for definitive alternative treatment,occurred in only one patient,who developed recurrent stenosis with increasing bile duct dilatation that required stent placement.CONCLUSION:Endoscopic therapy with a PEB is very effective for the treatment of AS after LT,and seems to significantly shorten the overall duration of endoscopic treatment by reducing the number of interventions needed to achieve LTCS.Anna Hüsing Holger Reinecke Vito R Cicinnati Susanne Beckebaum Christian Wilms Hartmut H Schmidt Iyad Kabar 2015World Journal of Gastroenterology2015,21,3:4
5Topology impacts TRAIL therapy: Differences in primary cancer growth and liver metastasis between orthotopic and subcutaneous xenotransplants of pancreatic ductal adenocarcinoma cells显示文摘Background: To study novel treatment modalities for pancreatic ductal adenocarcinoma(PDAC), we need to transfer the knowledge from in vitro to in vivo. It is important to mirror the clinical characteristics of the typically local invasive growth of pancreatic cancer and the distant spread resulting in liver metastasis. Notably, for xenotransplant studies using human specimen, two models, i.e. subcutaneous(s.c.) and orthotopic(o.t.) transplantation are widely used. Methods: The subcutaneously and orthotopically inoculated Colo357 Bcl-x L cell-derived tumors were directly compared with and without TNF-related apoptosis inducing ligand(TRAIL) treatment. The size of primary tumors, number of liver metastasis and the histologic markers Ki67, M30, TNF-α and CD31 were assessed. Results: Upon TRAIL treatment, the primary tumors did not change their size, neither in the s.c. nor in the o.t. approaches. But when s.c. was compared to o.t., the size of the s.c. tumors was more than twofold bigger than that of the o.t. tumors( P<0.01). However, mice with orthotopically inoculated PDAC cells developed liver metastasis upon TRAIL treatment much more frequently( n=13/17) than mice with subcutaneously inoculated PDAC cells( n=1/11)( P<0.01). As a likely driving force for this increased metastasis, a higher TNF-α staining intensity in the o.t. tumors was observed by immunohistochemistry. Conclusions: These data from a direct side-by-side comparison underline the importance of the proper inoculation site of the PDAC cells. Local invasion and liver metastases are a hallmark of PDAC in the clinic;the o.t. model is clearly superior in reflecting this setting. Moreover, a serious side-effect of a possible new therapeutic compound became obvious only in the o.t. model.Bastian Kettler Anna Trauzold Christian Röder Jan-Hendrik Egberts Holger Kalthoff 2021Hepatobiliary & Pancreatic Diseases International2021,20,3:3
6Scenario Reduction Algorithms in Stochastic Programming显示文摘Holger Heitsch Werner R?misch 2003Computational Optimization and Applications (-)2003,,2:2
7Right Portal Vein Ligation Combined With In Situ Splitting Induces Rapid Left Lateral Liver Lobe Hypertrophy Enabling 2-Staged Extended Right Hepatic Resection in Small-for-Size Settings显示文摘Andreas A. Schnitzbauer Sven A. Lang Holger Goessmann Silvio Nadalin Janine Baumgart Stefan A. Farkas Stefan Fichtner-Feigl Thomas Lorf Armin Goralcyk Rüdiger H?rbelt Alexander Kroemer Martin Loss Petra Rümmele Marcus N. Scherer Winfried Padberg Alfred K? 2012Annals of Surgery2012,,3:2
8Use of artificial neural networks for modelling cyanobacteria Anabaena spp. in the River Murray, South Australia显示文摘Holger R Maier Graeme C Dandy Michael D Burch 1998Ecological Modelling1998,,2:2
9Genetic algorithms for reliability-based optimization of water distribution systems显示文摘Bryan A Tolson Holger R Maierl Angus R Simpson 2005Journal of Water Resources and Management2005,26,6:1
10Development and practical test of a weighable groundwater lysimeter for floodplain sites 显示文摘DOERTHE B S RALPH M E HOLGER R 2004Journal of Plant Nutrition and Soil Science2004,167,:1
11Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries 显示文摘Michael E Holger R Ralf J et al 1999Arterioscler Thromb Vasc Biol1999,19,:1
12Application of partial mutual information variable selection to ANN forecasting of water quality in water distribution systems 显示文摘Robert J M Graeme C D Holger R M 2008Environmental Modelling & Software2008,3,8:1
13Percutaneous left ventricular assist devices in acute myocardial infarction complicated by cardiogenic shock显示文摘HOLGER T SMALI ING R W SCHUI ER G C 2007Eur HeartJ2007,17,:1
14Genetic algorithms for reliability2based optimization of waterdistribution systems 显示文摘Bryan A Tolson Holger R Maierl Angus R Simp son 2004Journal of Water Resources andM anagem ent2004,,:1
15Augmented reality applications in re-habilitation to improve physical outcomes 显示文摘Hussain Al Holger R Leigh H 2012Phys Ther Rev2012,17,1:1
16Biochemical charac- terization of a U6 small nuclear RNA-specific termi- nal uridylyltransferase 显示文摘Ralf T Holger R Benecke B J 2003Eur J Biochem2003,270,:1
17Structural Basis for the Entrance into the Phenylpropanoid Metabolism Catalyzed by Phenylalaminne Ammonia-Lyase显示文摘Holger R Georg E S 2004Plant Cell2004,16,12:1
18Cerebral venous sinus thrombosis显示文摘Holger Allroggen R ichard J Abbott 2000Postgrad Med J2000,76,1:1
19Using a fiber stretcher as a fast phase modulator in a continuous wave terahertz spectrometer显示文摘Axel R Komalavalli T Holger S 2012J Opt SocAmB2012,29,4:1
20A fuzzy reinforce- ment learning approach for self-optimization of coverage in LTE networks 显示文摘Rouzbeh R Siegfried K Holger C 2010Bell Labs Technical Journal2010,15,3:1
返回顶部 每页显示:
共4页 首页 上一页 第1页 下一页 末页 /4 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费